A six month open label study of amiloride solution for inhalation and tobramycin solution for inhalation for the eradication of Burkholderia dolosa in patients with cystic fibrosis

Trial Profile

A six month open label study of amiloride solution for inhalation and tobramycin solution for inhalation for the eradication of Burkholderia dolosa in patients with cystic fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2011

At a glance

  • Drugs Amiloride (Primary) ; Tobramycin (Primary)
  • Indications Burkholderia infections; Cystic fibrosis-associated respiratory tract infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Last checked against ClinicalTrials.gov record.
    • 12 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top